Therapeutic Advances in Musculoskeletal Disease

Thank you for such a thought-provoking and comprehensive congress #EULAR2024! See you next year in Barcelona

An interesting late-breaking abstract from our Editor-in-Chief @DrPoddubnyy on the last day of #EULAR2024 presenting a novel study design to test treat-to-target for patient's with #AxialSpondyloarthritis

Looking forward to #EULAR2024 Day 3!

Fantastic talk from Prof. Neil Basu at #EULAR2024 this morning on how partitioning musculoskeletal conditions into distinct pain mechanisms is not the most effective way to treat a patient's pain

Exciting new research on pre-diagnostic proteomic biomarkers for #Gout and predictive biomarkers for treatment response in #RheumatoidArthritis (and more!) presented at the first abstract session of #EULAR2024 yesterday! Co-moderated by our Associate Editor @ChristianDejaco

A great first day at #EULAR2024. Especially @Lupusreference's engaging and accessible talk about what's on the horizon for #Lupus.

Using natural language processing to explore characteristics and management of patients with SpA (axSpA and PsA) in Spain. Check it out here: journals.sagepub.com/doi/10.1177/17… @DiegoBenavent

Introducing our NEW Special Collection on Artificial Intelligence in Rheumatology! 📢 Open for submissions! Share your insights with us! 📝👩‍💻 #AI #Rheumatology @DiegoBenavent @vincevenerito @xabiermich

A new Special Collections is underway! Psoriatic arthritis: Clinical, Diagnostic, and Therapeutic Aspects. Guest Editors: @FragoulisGeorge @SteZhao Find out more here: journals.sagepub.com/page/tab/speci…

Now published in @TAMuscDis: The effect of an IL-17A inhibitor on axial manifestations in patients with psoriatic arthritis from two Phase III clinical studies, SPIRIT-P1 and SPIRIT-P2. #PsA #psoriaticarthritis Click here to access the full article: e.lilly/469DQko

How can we improve outcomes for PsA patients? Read more for the HIPPOCRATES programme. journals.sagepub.com/doi/10.1177/17… @StefanSiebert1

Ixekizumab is effective in patients with Axial-PsA. Results from two phase III trials. journals.sagepub.com/doi/full/10.11… @DrPoddubnyy

New study shows Abatacept remains effective & safe in RA patients with previous malignancy, challenging previous inconsistent reports. 🩺🔬 #RheumatoidArthritis #MedicalResearch #abatacept Check this out! bit.ly/3OH8WJd

We are celebrating today as Therapeutic Advances in Rare Disease is now indexed in PubMed & Scopus! A great milestone for the Journal! Congratulations @Urvalind @maurizioscarpa @BCH_Rare @JemimaMellerio @votrubam @MariyaMoosajee @oligogirl @roon_mom @DrJohnBladen @SageJournals

🔬 Excited to be part of #EULAR2023! We've curated a special collection of articles just for this conference. Share knowledge, foster connections, spark dialogues. Let's change the future together! 📷#Rheumatology #OpenAccess @SageClinMed ➡️bit.ly/3ovhb1W

10000 views reached !!! 🎉🎉🎉🎉🎉 Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge @TAMuscDis Dima Alina, Jurcut Ciprian, Chasset Francois, Felten Renaud, Arnaud Laurent journals.sagepub.com/doi/full/10.11…

New article online! Risk factors for the long-term incidence and progression of knee osteoarthritis in older adults: role of nonsurgical injury bit.ly/3WFgeRj @SageClinMed @TAMuscDis #OpenAccess #Osteoarthritis #KneeOsteoarthritis #TASeries #RheumTwitter

Any use of DMARDs in hand OA? Check out this updated review published in TAMD journals.sagepub.com/doi/full/10.11…

🔬 Years of research, still no effective disease-modifying #osteoarthritis drugs (DMOADs) 💊. #MRI could be the key to success in future DMOAD trials. @ali_guermazi @FrankRoemer1 Michel D. Crema, Mohamed Jarraya, Ali Mobasheri, Daichi Hayashi Read more ➡️bit.ly/3N3Y8pl

📢 New review highlights the urgent need for more effective treatments for hand #osteoarthritis. 🦴💊 From Sara Tenti, @olibruyere, Sara Cheleschi, Jean-Yves Reginster, @ilmannato, Antonella Fioravanti bit.ly/3L4jvFe